Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Aboudara

Showing results (21-30 of 21) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 21 results.
The Lancet. Diabetes & Endocrinology|July 24, 2021
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trialMikhail N Kosiborod, Russell Esterline, Remo H M Furtado, et al.
Pageof 3

Showing results (21-30 of 21) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 21 results.
The Lancet. Diabetes & Endocrinology|July 24, 2021
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trialMikhail N Kosiborod, Russell Esterline, Remo H M Furtado, et al.
Pageof 3